MERCOGLIANO MF; BRUNI S; MAURO F; SCHILLACI R

Emerging Targeted Therapies for HER2-Positive Breast Cancer

Cancers; Año: 2023 vol. 15

BRUNI S; MERCOGLIANO MF; MAURO, F; CORDO-RUSSO, ROSALÍA; SCHILLACI R

Cancer immune exclusion: breaking the barricade for a successful immunotherapy

Frontiers in Oncology; Año: 2023 vol. 13

BRUNI, S; MAURO F; PROIETTI C; CORDO-RUSSO, ROSALÍA; RIVAS M; INURRIGARRO G; DUPONT A; ROCHA D; FERNÁNDEZ, ELMER A.; GIL DEZA E; LOPEZ DELLA VECCHIA, D; BARCHUK, SABRINA; FIGURELLI, SILVINA; LASSO D; FRIEDRICH A; SANTILLI MC; REGGE V; LEBERSZTEIN, G; LEVIT, C; ANFUSO, F; CASTIGLIONE, T; ELIZALDE PV; MERCOGLIANO MF; SCHILLACI R

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

Journal for ImmunoTherapy of Cancer; Año: 2023 vol. 11

MADERA S; IZZO F; CHERVO, MF; DUPONT A; CHIAUZZI V; BRUNI, S; PERILLO, E; DE MARTINO, MARA; MONTERO D; LEVIT, C; LEBERSZTEIN, G; ANFUSO, F; ROLDAN DEAMICIS A; MERCOGLIANO, MARÍA F.; PROIETTI CJ; SCHILLACI R.; ELIZALDE PV; CORDO-RUSSO, ROSALÍA

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer

Cell Death & Disease; Año: 2022

MERCOGLIANO MF; BRUNI S; MAURO, F; ELIZALDE PV; SCHILLACI, R

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy

Cancers; Año: 2021 vol. 13

MADERA S; CHERVO, MF; CHIAUZZI V; PEREYRA, M; VENTURUTTI, L; IZZO F; ROLDÁN DEAMICIS, A; GUZMAN, P; ROA JC; CENCIARINI, ME; BARCHUK, SABRINA; FIGURELLI, SILVINA; LOPEZ DELLA VECCHIA, D; LEVIT, C; LEBERSZTEIN, G; ANFUSO, F; CASTIGLIONE, T; CORTESE E; ARES S; GIL DEZA E; GERCOVICH FG; PROIETTI, CJ; SCHILLACI, ROXANA; CORDO-RUSSO, ROSALÍA; ELIZALDE PV

Nuclear PDCD4 expression defines a subset of luminal B-like breast cancers with good prognosis

Hormones and Cancer; Año: 2020

DE MARTINO M; TKACH, M; BRUNI S; ROCHA, D; MERCOGLIANO MF; CENCIARINI, ME; CHERVO, MF; PROIETTI, CJ; DINGLI, F; LOEW, D; FERNÁNDEZ, ELMER A.; ELIZALDE, PV; PIAGGIO E; SCHILLACI R

Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cellnonautonomous activity suitable for cancer immunotherapy

Oncoimmunology; Lugar: Filadelfia; Año: 2020

MERCOGLIANO MF; BRUNI S; ELIZALDE, PV; SCHILLACI R

Tumor necrosis factor alpha blockade: an opportunity to tackle breast cancer

Frontiers in Oncology; Lugar: Lausanne; Año: 2020

CHERVO, MF; CORDO-RUSSO, ROSALÍA; PETRILLO E; IZZO F; DE MARTINO M; BELLORA N; CENCIARINI, M; SANTA MARIA DE LA PARRA, L; PEREYRA, M; GÜTTLEIN L; PODHAJCER O; DANIOTTI JL; DUPONT A; BARCHUK, SABRINA; FIGURELLI, SILVINA; LOPEZ DELLA VECCHIA, D; ROA JC; GUZMAN, P; PROIETTI CJ; SCHILLACI R; ELIZALDE PV

Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth

Oncogene; Año: 2020 vol. 39 p. 6245 - 6262

BESSO, MJ; ROSSO, M; LAPYCKYJ, L; MOIOLA, CP; MATOS, ML; MERCOGLIANO MF; SCHILLACI R; REVENTOS, J; COLAS, E; GIL-MORENO, A; WERNICKE, A; ORTI, R; VAZQUEZ-LEVIN, MH

FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-b1 and NF-kB Pathways

Frontiers in Oncology; Lugar: Lausanne; Año: 2019

MERCOGLIANO MF; DE MARTINO M; VENTURUTTI, L; RIVAS, MA; PROIETTI, CJ; INURRIGARRO G; FRAHM I; ALLEMAND D; GIL DEZA E; ARES S; GERCOVICH FG; GUZMÁN P; ROA JC; ELIZALDE, PV; SCHILLACI R

TNFalpha-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer

CLINICAL CANCER RESEARCH; Año: 2017 vol. 23 p. 636 - 648

MERCOGLIANO, MARÍA F.; INURRIGARRO, GLORIA; DE MARTINO, MARA; VENTURUTTI, LEANDRO; RIVAS, MARTÍN A.; CORDO-RUSSO, ROSALÍA; PROIETTI, CECILIA J.; FERNÁNDEZ, ELMER A.; FRAHM, ISABEL; BARCHUK, SABRINA; ALLEMAND, DANIEL H.; FIGURELLI, SILVINA; DEZA, ERNESTO GIL; ARES, SANDRA; GERCOVICH, FELIPE G.; CORTESE, EDUARDO; AMASINO, MATÍAS; GUZMÁN, PABLO; ROA, JUAN C.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer

BMC CANCER; Año: 2017 vol. 17

VELASQUEZ LN; MILILLO MA; DELPINO MV; TROTTA A; MERCOGLIANO MF; POZNER RG; SCHILLACI R; ELIZALDE PV; GIAMBARTOLOMEI GH; BARRIONUEVO, P

Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway

IMMUNOLOGY AND CELL BIOLOGY; Lugar: Londres; Año: 2017 vol. 95 p. 388 - 398

ELIZALDE PV; ROSALIA CORDO RUSSO; CHERVO, MF; SCHILLACI R

ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy

ENDOCRINE - RELATED CANCER; Lugar: Bristol; Año: 2016 vol. 23 p. 243 - 247

VINUESA, A; POMILLO, C; MENAFRA, M; BONAVENTURA,MM; GARAY,L; MERCOGLIANO MF; SCHILLACI R,; LUX-LANTOS, V; BRITES, F; BEAUQUIS, J; SARAVIA, F

Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity.

PSYCHONEUROENDOCRINOLOGY; Año: 2016 vol. 72 p. 22 - 33

VENTURUTTI, L; ROSALIA CORDO RUSSO; RIVAS, MA; MERCOGLIANO MF; IZZO F; OAKLEY RH; PEREYRA, M; DE MARTINO M; PROIETTI CJ; YANKILEVICH P; ROA JC; GUZMÁN P; CORTESE E; ALLEMAND D; HUANG T H-M; CHARREAU EH; CIDLOWSKI J; SCHILLACI R; ELIZALDE PV

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

ONCOGENE; Lugar: Londres; Año: 2016

CORIA, L; IBAÑEZ AE; TKACH, M; SABBIONE, F; BRUNO, L; CARAVAJAL, MV; BERQUER, PM; BARRIONUEVO, P; SCHILLACI R; TREVANI, AS; GIAMBARTOLOMEI G; K PASKEVICH; CASSATARO J

A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses

JOURNAL OF IMMUNOLOGY; Lugar: Bethesda; Año: 2016 vol. 196 p. 4014 - 4029

VENTURUTTI, L; ROMERO, L; URTREGER A; CHERVO, MF; ROSALIA CORDO RUSSO; MERCOGLIANO MF; INURRIGARRO G; PEREYRA, M; PROIETTI CJ; IZZO F; DIAZ FLAQUÉ, MC; SUNDBLAD, VICTORIA; ROA JC; GUZMÁN P; BAL DE KIER JOFFÉ E; CHARREAU EH; SCHILLACI R; ELIZALDE PV,

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

ONCOGENE; Año: 2015

PROIETTI CJ; IZZO F; DIAZ FLAQUE, MC; ROSALIA CORDO RUSSO; VENTURUTTI, L; MERCOGLIANO MF; DE MARTINO M; PINEDA V; MUÑOZ S; GUZMÁN P; ROA JC; SCHILLACI R; ELIZALDE PV

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

MOLECULAR ENDOCRINOLOGY; Año: 2015 vol. 29 p. 1468 - 1485

WIEBE J; RIVAS MA; MERCOGLIANO MF; ELIZALDE PV; SCHILLACI R

Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY; Año: 2015 vol. 149 p. 27 - 34

ROSALIA CORDO RUSSO; BEGUELIN W; DIAZ FLAQUE, MC; PROIETTI C; VENTURUTTI, L; NATALIA GALIGNIANA; TKACH, M; GUZMÁN P; ROA JC; O´BRIEN NA; CHARREAU EH; SCHILLACI R; ELIZALDE PV.

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

ONCOGENE; Año: 2015 vol. 34 p. 3413 - 3428

GASPAROTO T; DE OLIVEIRA CE; THOMAZINI DE FREITAS L; RAMOS PINHEIRO C; HORI JI; POMPERMAIER GARLET G; CAVASSANI KA; SCHILLACI R; SANTANA DA SILVA S; ZAMBONI DS; CAMPANELLI AP

Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.

PLOS ONE; Lugar: San Francisco; Año: 2014

IZZO F; MERCOGLIANO MF; VENTURUTTI, L; TKACH M; INURRIGARRO G; SCHILLACI R,; CERCHIETTI L; ELIZALDE PV; PROIETTI CJ

Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth

BREAST CANCER RESEARCH; Lugar: Londres; Año: 2014 vol. 16

TKACH M; ROSEMBLIT C; RIVAS MA; PROIETTI CJ; DÍAZ FLAQUÉ MC; MERCOGLIANO MF; BEGUELIN W; MARONNA E; PABLO GUZMÁN; GERCOVICH FG; GIL DEZA E; ELIZALDE PV; SCHILLACI R

P42/P44 MAPK-MEDIATED STAT3 SER727 PHOSPHORYLATION IS REQUIRED FOR PROGESTIN-INDUCED FULL ACTIVATION OF STAT3 AND BREAST CANCER GROWTH

ENDOCRINE - RELATED CANCER; Lugar: Bristol; Año: 2013 vol. 20 p. 197 - 212

DIAZ FLAQUE, MC; NATALIA GALIGNIANA; BEGUELIN W; VICARIO R; PROIETTI CJ; ROSALIA CORDO RUSSO; RIVAS MA; TKACH, M; GUZMÁN P; ROA JC; PINEDA V; MUÑOZ S; MERCOGLIANO MF; CHARREAU EH; YANKILEVICH P; SCHILLACI R; ELIZALDE PV

Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy

BREAST CANCER RESEARCH; Lugar: Londres; Año: 2013 vol. 15 p. 118 - 118

DÍAZ FLAQUÉ M; VICARIO R; PROIETTI CJ; IZZO F; SCHILLACI R; ELIZALDE PV

Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.

STEROIDS; Lugar: Amsterdam; Año: 2013 vol. 78 p. 559 - 567

TKACH M; CORIA, L; ROSEMBLIT, C; RIVAS MA; PROIETTI, CJ; DIAZ FLAQUE, MC; BEGUELIN, W; FRAHM I; CHARREAU EH; CASSATARO J; ELIZALDE PV; SCHILLACI R

Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells

JOURNAL OF IMMUNOLOGY; Lugar: Bethesda; Año: 2012 vol. 189 p. 1162 - 1172

DURFORT, T; TKACH M; MESCHANINOVA, MI; RIVAS, MA; ELIZALDE, PV; VENYAMINOVA, AG; SCHILLACI, R; FRANCOIS; JC

Small Interfering RNA Targeted to IGF-IR Delays Tumor Growth and Induces Proinflammatory Cytokines in a Mouse Breast Cancer Model

PLOS ONE; Año: 2012 vol. 7 p. 29213 - 29213

SCHILLACI R; GUZMÁN P; CAYROL, F; BEGUELIN W; DIAZ FLAQUE, MC; PROIETTI CJ; PINEDA V; PALAZZI J; FRAHM I; CHARREAU E H; MARONNA E; ROA JC; ELIZALDE PV

Clinical Relevance of ErbB-2/HER2 Nuclear Expression in Breast Cancer

BMC CANCER; Lugar: Londres; Año: 2012 vol. 12 p. 74 - 78

RIVAS, MA; VENTURUTTI, L; HUANG Y-W; SCHILLACI R; HUANG T H-M; ELIZALDE PV

.Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

BREAST CANCER RESEARCH; Lugar: Londres; Año: 2012 vol. 14 p. 77 - 77

PROIETTI, CJ; BEGUELIN, W; DIAZ FLAQUE, MC; CAYROL, F; RIVAS, MA; TKACH, M; CHARREAU, EH; SCHILLACI, R; ELIZALDE, PV

. Novel role of Signal Transducer and Activator of Transcription 3 as a Progesterone Receptor coactivator in breast cancer.

STEROIDS; Año: 2011 vol. 76 p. 318 - 392

RIVAS MA, TKACH M, BEGUELIN W, PROIETTI CJ, ROSEMBLIT C, CHARREAU EH, ELIZALDE PV, SCHILLACI, R.

Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kB activation and breast cancer cell proliferation.

BREAST CANCER RESEARCH AND TREATMENT; Año: 2010 vol. 122 p. 111 - 124

BEGUELIN W; DIAZ FLAQUÉ MC; PROIETTI CJ; CAYROL F; RIVAS MA; TKACH M; ROSEMBLIT C; TOCCI JM; CHARREAU EH; SCHILLACI R; ELIZALDE PV.

PR induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect; ErbB-2 function as coactivator of Stat3.

MOLECULAR AND CELLULAR BIOLOGY; Año: 2010 vol. 30 p. 5456 - 5472

PROIETTI C. J; ROSEMBLIT C; BEGUELIN W; RIVAS MA; CHARREAU E H; SCHILLACI R; ELIZALDE PV

Activation of Stat3 by Heregulin/ErbB-2 Through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth

MOLECULAR AND CELLULAR BIOLOGY; Año: 2009 vol. 29 p. 1249 - 1265

RIVAS, MARTIN; CARNEVALE, ROMINA; PROIETTI, CECILIA; ROSEMBLIT, CINTHIA; BEGUELIN, WENDY; SALATINO, MARIANA; CHARREAU, EDUARDO; FRAHM, ISABEL; SAPIA, SANDRA; BROUCKAERT, PETER; ELIZALDE, PATRICIA; SCHILLACI, ROXANA

TNFa acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways

EXPERIMENTAL CELL RESEARCH; Año: 2008 vol. 314 p. 509 - 529

CARNEVALE R; PROIETTI CJ; SALATINO M; URTREGER A; PELUFFO G; EDWARDS DP; BOONYARATANAKORNKIT V; CHARREAU EH; BAL DE KIER JOFFÉ E; SCHILLACI R; ELIZALDE PV

Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on PR capacity to activate cytoplasmic signaling pathways

MOLECULAR ENDOCRINOLOGY; Lugar: Baltimore; Año: 2007 vol. 21 p. 1335 - 1358

SALATINO M; BEGUELIN W; PETERS MG; CARNEVALE R; PROIETTI CJ; GALIGNIANA M; VEDOY GC; SCHILLACI R; CHARREAU EH; SOGAYAR MC; ELIZALDE PV

Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation

ONCOGENE; Lugar: Inglaterra; Año: 2006 vol. 25 p. 7723 - 7739

SCHILLACI R; SALATINO M; CASSATARO J; PROIETTI CJ; GIAMBARTOLOMEI GH; RIVAS M; CARNEVALE R; CHARREAU EH; ELIZALDE PV

Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+-Response Involving Fas/Fas Ligand Cytotoxic Pathway.

JOURNAL OF IMMUNOLOGY; Lugar: Baltimore; Año: 2006 vol. 176 p. 3426 - 3437

PROIETTI C; SALATINO M; ROSEMBLIT C; CARNEVALE R; PECCI A; KORNBLIHTT AR; MOLINOLO AA; FRAHM I; CHARREAU EH; SCHILLACI R; ELIZALDE PV

Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) Via Jak and Src-Dependent Mechanism in Breast Cancer Cells.

MOLECULAR AND CELLULAR BIOLOGY; Año: 2005 vol. 25 p. 4826 - 4840

SCHILLACI R; GALEANO A; BECU-VILLALOBOS D; SPINELLI O; SAPIA S; BEZARES RF

Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukemia.

BRITISH JOURNAL OF HAEMATOLOGY; Lugar: england; Año: 2005 vol. 130 p. 58 - 66

SALATINO M; SCHILLACI R; PROIETTI C. J; CARNEVALE R; CHARREAU E.H; ELIZALDE PV.

Bloqueo del receptor del factor de crecimiento semejante a la insulina tipo I utilizando oligodeoxinucleótidos antisentido en cáncer de mama.

MEDICINA; Lugar: Buenos Aires; Año: 2004 vol. 64 p. 129 - 134

SALATINO M; SCHILLACI R; PROIETTI CJ; CARNEVALE R; FRAHM I; MOLINOLO A; IRIBARREN AM.; CHARREAU EH; ELIZALDE PV

Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor acti

ONCOGENE; Año: 2004 vol. 23 p. 5161 - 5174

SEGRETIN, ME; GALEANO A; ROLDAN, A; SCHILLACI R

Insulin-like growth factor-1 receptor regulation in activated human T lymphocytes.

HORMONE RESEARCH; Año: 2003 vol. 59 p. 276 - 280

SORIANELLO, E; SCHILLACI, R; CHAMSON-REIG, A; LUX-LANTOS, V; LIBERTUN, C

Actions of immunosuppressor drugs on the development of an experimental ovarian tumor.

EXPERIMENTAL BIOLOGY AND MEDICINE; Año: 2002 vol. 227 p. 658 - 664

, SALATINO M; LABRIOLA, L; SCHILLACI R; CHARREAU EH; ELIZALDE PV

Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.

EXPERIMENTAL CELL RESEARCH; Lugar: USA; Año: 2001

BROCARDO MG; SCHILLACI R; GALEANO A; RADRIZZANI, M; WHITE, V; GUERRICO, AG; SANTA-COLOMA, TA; ROLDAN, A

Early effects of insulin-like growth factor-1 in activated human T lymphocytes.

JOURNAL OF LEUKOCYTE BIOLOGY; Año: 2001 vol. 70 p. 297 - 305

SCHILLACI R; BROCARDO MG; GALEANO A; ROLDAN, A

Downregulation of insulin-like growth factor-1 receptor (IGF-1R) expression in human T lymphocyte activation.

CELLULAR IMMUNOLOGY; Año: 1998 vol. 183 p. 157 - 161

ROLDAN, A; GOGG, S; FERRINI, M; SCHILLACI R; DE NICOLA, AF

Glucocorticoid regulation of in vitro astrocyte phagocytosis

BIOCELL; Lugar: Mendoza; Año: 1997 vol. 21 p. 83 - 89

SCHILLACI R; BROCARDO MG; ROLDAN, A

Co-operative effect between insulin-like growth factor-1 and interleukin-2 on DNA synthesis and interleukin-2 receptor-alpha chain expression in human lymphocytes.

IMMUNOLOGY AND CELL BIOLOGY; Año: 1995 vol. 73 p. 340 - 345

SCHILLACI R; EUGUI, EM; ROLDAN, A

Insulin effect on interleukin 1 (IL-1) and interleukin 6 (IL-6) production by lipopolysaccharide-stimulated human monocytes.

HORMONE AND METABOLIC RESEARCH; Año: 1994 vol. 26 p. 113 - 115

SCHILLACI R; RIBAUDO, CM; RONDINONE, CRISTINA; ROLDAN, A

Role of insulin-like growth factor-1 on the kinetics of human lymphocytes stimulation in serum-free culture medium.

IMMUNOLOGY AND CELL BIOLOGY; Año: 1994 vol. 72 p. 300 - 305

RONDINONE, CRISTINA; SCHILLACI R; DEL CASTILLO, MB; ROLDAN, A

Inhibitory effect of 11 beta-hydroxypregna-1,4-diene-3,20-dione (delta HOP) on lymphocyte proliferation.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY; Año: 1991 vol. 88 p. 311 - 316

RONDINONE, CRISTINA; SCHILLACI R; LANTOS, C; ROLDAN, A

Appearance and persistence of 11 beta-hydroxypregna-1,4-diene-3,20-dione (delta HOP) effect "in vivo

Acta Physiol Pharmacol Latinoam.; Año: 1989 vol. 39 p. 181 - 189

ROLDAN, A; CHARREAU EH; SCHILLACI R,; EUGUI, EM; ALLISON, AC

Insulin-like growth factor-1 increases the mitogenic response of human peripheral blood lymphocytes to phytohemagglutinin.

IMMUNOLOGY LETTERS; Lugar: Amsterdam; Año: 1989 vol. 89 p. 5 - 8